New discoveries are reshaping scientific understanding of psychedelic compounds and their potential role in treating mental health conditions. The Atlantic explores the research driving this rapidly evolving field.

The November 12 restrictions on hemp-derived THC beverages may have unintended consequences for public health. Amanda Parker argues that Congress should pursue responsible regulation focused on safety, consumer protection, and harm reduction rather than restricting access to products that many adults use as an alternative to alcohol.

The American Alternative Care Policy Network (AACPN) has announced a national policy agenda focused on expanding access to evidence-based integrative and alternative healthcare. Through its Alternative Care Access Campaign, Psychedelic Research Initiative, and Hemp Beverage Policy Initiative, AACPN seeks to advance healthcare access, scientific research, patient choice, and evidence-based policy for veterans, trauma survivors, first responders, and other underserved populatio

AACPN applauds Connecticut’s enactment of Public Act 26-108, expanding the state’s psychedelic-assisted therapy pilot program and supporting continued clinical research involving MDMA and psilocybin therapies for veterans, first responders, trauma survivors, and individuals living with treatment-resistant mental health conditions.

The American Alternative Care Policy Network has launched a new initiative opposing upcoming federal restrictions on hemp-derived THC beverages and advocating for responsible, science-based regulation focused on consumer safety, harm reduction, trauma recovery, and evidence-based alternative care policy.

The TSA’s updated guidance on medical marijuana travel marks a significant step toward more practical and patient-centered federal cannabis policy. AACPN examines what the change means for veterans, medical cannabis patients, and the future of domestic travel reform.